Document is current
Any future updates will be listed below
-
Authors
Towbin, Alexander J. https://orcid.org/0000-0003-1729-5071
Ye, Wen
Huang, Suiyuan
Karmazyn, Boaz W. https://orcid.org/0000-0003-1674-1789
Molleston, Jean P. https://orcid.org/0000-0002-8708-0298
Masand, Prakash
Leung, Daniel H.
Chang, Samuel
Narkewicz, Michael R.
Alazraki, Adina L. https://orcid.org/0000-0003-1094-282X
Freeman, A. Jay https://orcid.org/0000-0002-3399-3390
Otto, Randolph K. https://orcid.org/0000-0003-1273-7176
Green, Nicole
Kamel, Ihab R.
Karnsakul, Wikrom W. https://orcid.org/0000-0001-7288-5459
Magee, John C. https://orcid.org/0000-0001-8416-7905
Tkach, Jean https://orcid.org/0000-0003-4593-7481
Palermo, Joseph J.
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NCT02979340)
- License Information
-
More Information
Article History
Received: 20 October 2022
Revised: 8 June 2023
Accepted: 17 June 2023
First Online: 28 July 2023
Declarations
: Alexander J. Towbin: Grant funding from the Cystic Fibrosis Foundation. Received consulting fees from Applied Radiology, Author Royalties from Elsevier, and funded travel from KLAS, and Merative.
: Jean P. Molleston: Grant funding from the Cystic Fibrosis Foundation.
: Daniel H. Leung: Grant funding from the Cystic Fibrosis Foundation. Medical Advisory Board Vertex.
: Michael R. Narkewicz: Consultant for Vertex, Gilead Research, AbbVie.
: A. Jay Freeman: Grant funding from the Cystic Fibrosis Foundation, National Institutes of Health, Travere Therapeutics, Allergan. Consultant for Takeda and AbbVie.
: Wikrom W. Karnsakul: Research support and Consultant Albireo, Travere, Mirum, Gilead, AbbVie.
: Rest: none
